MedPacto Executives Acquire 100,000 Shares of Company Stock on the Market

MedPacto announced on the 5th that CEO Kim Sung-jin and President Woo Jung-won, along with other executives, purchased approximately 100,000 shares of the company's stock on the open market.

This marks the first time in three years since January 2022, when CEO Kim Sung-jin purchased company shares worth 1 billion KRW, that MedPacto executives have bought company stock. Six executives participated in the stock purchase, including Mrs. Kim Young-won, the wife of CEO Kim Sung-jin.

CEO Kim Sung-jin acquired 31,882 shares, President Woo Jung-won 30,000 shares, and other department head-level executives along with Mrs. Kim Young-won purchased 43,946 shares, totaling 105,828 shares bought by MedPacto executives and affiliates.

A MedPacto representative explained, "This stock purchase demonstrates the company's commitment to responsible management and enhancing corporate value as key goals in management and research and development," adding, "We will actively engage in market communication to boost the stock price and strengthen shareholder-friendly policies."

The executives' stock purchase expresses confidence in the company's growth potential and can send a positive signal to the market.

MedPacto is advancing clinical development of new pipelines including the anti-cancer drug ‘TME-DP (TARGETi)’, which targets the tumor microenvironment, and the bone disease treatment 'MP2021'. The company is also working on expanding indications for the existing TGF-beta (β) inhibitor anti-cancer drug ‘Becatosept’.